<DOC>
	<DOC>NCT01487226</DOC>
	<brief_summary>Purpose Primary endpoint - To evaluate the 3-year disease free survival Second endpoints - To evaluate the 3-year &amp; 5-year overall survival To analyze the toxicity and the quality of life</brief_summary>
	<brief_title>Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>cervical cancer stage Ia2IIa histology; squamous, adeno, adenosquamous subtype age; 20∼70 years performance status; GOG 0∼2 no medical illness hematologic, renal, hepatic function; normal grossly no residual disease histologically confirmed lymph nodes metastases no parametrial extension and negative resection margin number of retrieved lymph nodes; ≥ 20 patients with grade 2 peripheral neuropathy patients with uncontrolled infection</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Cervical cancer</keyword>
</DOC>